Except for the above RCTs, there were some additional trails registered with the aim of exploring the effectiveness of TYK2 inhibitors on inflammatory bowel disease and systemic lupus erythematosus as well as assessing safety (Supplementary Table S15). Here, TYK2 is linked to systemic lupus erythematosus.